Healthcare
Voyageur Pharmaceuticals Ltd.(VYYRF)
Live Price
Offline$0.015
-76.92% today
1Y Change
-57.24%
Window
Jun 20, 2025 โ Jun 16, 2026
- Market Cap
- $20.00M
- Revenue Growth
- 0.0%
- EPS Growth
- -71.0%
- Dividend Yield
- 0.0%
Coverage: 255 bars ยท Jun 20, 2025 โ Jun 16, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Voyageur Pharmaceuticals Ltd. (VYYRF) is a Healthcare stock with a market cap of $20.00M and listed on OTC. The stock last traded around $0.01 and down 57.2% across the available one-year price window (Jun 20, 2025 โ Jun 16, 2026). Baseline metrics include revenue growth of 0.0%, EPS growth of -71.0%, a dividend yield of 0.0%. What stands out right now is revenue 0.0%, EPS -71.0%, free cash flow -855.9% with operating margin -10803.3% and ROIC -477.3%. Valuation already assumes a fairly strong business story at price/sales 576.9. Overall, the current profile looks closer to a turnaround or cyclical reset than a generic broad-market placeholder. Stock Foundry combines VYYRF price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Below sector median
0.0% vs +7.6% peer median
Operating Margin
Below sector median
-10803.3% vs +19.4% peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report is on the board
2026 was reported on Apr 24, 2026, but the surprise data is still limited.
The operating picture looks softer than before
Revenue is at 0.0% and EPS is at -71.0%, with operating margin around -10803.3%.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged 0.0% over the next 5 trading days and finished higher after 0 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS ฮ | 1D | 5D | 20D |
|---|---|---|---|---|
2026 Apr 24, 2026 | โ | +0.0% | +0.0% | -24.8% |
2026 Apr 1, 2026 | โ | +0.0% | +0.0% | -9.1% |
2026 Mar 27, 2026 | โ | +0.0% | +0.0% | -9.1% |
Benchmark Comparison
Normalized Performance vs SPY
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
VYYRF
โ
Normalized return
SPY
โ
S&P 500
Excess Return
โ
Relative to SPY
VYYRF Max Drawdown
-98.62%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for VYYRF and SPY.
Company Overview
Voyageur Pharmaceuticals Ltd.
Other OTC
Voyageur Pharmaceuticals Ltd. focuses on the development of active pharmaceutical ingredients minerals. The company intends to develop barium and iodine radiocontrast products and bromine based pharmaceutical products. It holds 100% interest in three barium sulfate deposits, including two properties suitable in grade for the pharmaceutical barite marketplace located in British Columbia, Canada; and interests in a high-grade iodine, lithium, and bromine brine project in Utah, the United States. The company was formerly known as Voyageur Minerals Ltd. and changed its name to Voyageur Pharmaceuticals Ltd. in December 2019. Voyageur Pharmaceuticals Ltd. is headquartered in Calgary, Canada.
- Leadership
- Brent Willis
- IPO Date
- Oct 19, 2017
- Employees
- 6
- Street Address
- 339โ50th Avenue SE
- Mailing
- Calgary, AB, T2G 2B3
- Region
- Calgary, AB, CA
- Reporting Currency
- USD
- Investor Line
- 587 779 6166
- Last Updated
- May 5, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- โ
- EV/EBITDA
- โ
- Price/Sales
- 576.9
- Price/Book
- 27.0
Growth
- Revenue
- 0.0%
- EPS
- -71.0%
- Free Cash Flow
- -855.9%
Profitability
- Gross Margin
- -4359.0%
- Operating Margin
- -10803.3%
- Net Margin
- -10796.3%
- ROE
- -313.1%
- ROIC
- -477.3%
Balance Sheet
- Debt/Equity
- 0.06
- Current Ratio
- 0.18
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.